A Phase I Study to Evaluate Safety and Pharmacokinetics of SAR408701 Administered Intravenously as Monotherapy in Japanese Patients With Advanced Malignant Solid Tumors
Latest Information Update: 11 Jan 2023
At a glance
- Drugs Tusamitamab ravtansine (Primary) ; Dexamethasone; Diphenhydramine; Naphazoline
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Sanofi
- 06 Jan 2023 Status changed from active, no longer recruiting to completed.
- 03 Jan 2023 Planned End Date changed from 31 Jan 2023 to 31 Mar 2023.
- 22 Dec 2022 Planned End Date changed from 31 Mar 2023 to 31 Jan 2023.